RAPP Stock Analysis: Rapport Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 1.864m USD | 12M Return: 229.9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 12.9M
Warnings
Tailwinds
Seasonality 2 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Rapport Therapeutics, Inc. (NASDAQ: RAPP) is a U.S.-based, clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, that is developing small molecule therapies for central nervous system (CNS) disorders. Its lead candidate, RAP-219, is an investigational molecule designed to selectively inhibit TARPy8-containing AMPARs, with initial development focused on focal epilepsy, peripheral neuropathic pain, and bipolar disorder. The company is also advancing earlier-stage nicotinic acetylcholine receptor (nAChR) programs targeting chronic pain and migraine (a6 nAChR) and hearing/vestibular disorders (a9a10 nAChR). The company was incorporated in 2022 (formerly Precision Neuroscience NewCo, Inc.) and completed its IPO in June 2024.
As a clinical-stage biopharmaceutical company, Rapport does not yet have approved products or commercial revenue, and its value is largely tied to the clinical progress of its pipeline. CNS drug development is typically characterized by long development timelines, high failure rates, and significant unmet medical need, which can make the segment both capital-intensive and commercially attractive if assets succeed in late-stage trials.
- RAP-219 Phase 2 focal epilepsy data readout approaches
- Cash burn rate and runway remain investor focus
- Pipeline expansion advances nAChR chronic pain and migraine programs
| Net Income: -107.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.16 > 0.02 and ΔFCF/TA 6.65 > 1.0 |
| NWC/Revenue: 2.33k% < 20% (prev 39.1k%; Δ -36.8k% < -1%) |
| CFO/TA -0.16 > 3% & CFO -80.3m > Net Income -107.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 27.08 > 1.5 & < 3 |
| Outstanding Shares: last quarter (47.2m) vs 12m ago 144.9% < -2% |
| Gross Margin: 95.0% > 18% (prev -29.31%; Δ 124.3% > 0.5%) |
| Asset Turnover: 5.00% > 50% (prev 0.24%; Δ 4.76% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.94 (Total Current Assets 484.7m - Total Current Liabilities 17.9m) / Total Assets 497.6m |
| B: -0.51 (Retained Earnings -255.1m / Total Assets 497.6m) |
| C: -0.30 (EBIT TTM -119.1m / Avg Total Assets 399.8m) |
| D: 18.08 (Book Value of Equity 471.5m / Total Liabilities 26.1m) |
| Altman-Z'' = 21.46 = AAA |
As of July 08, 2026, the stock is trading at USD 39.72 with a total of 861,859 shares traded. Over the past week, the price has changed by -1.66%, over one month by +8.29%, over three months by +18.60% and over the past year by +229.90%.
Current recommended Stop Loss: 36.70 (which is 7.6% or 1.3 ATR below the current price).
Rapport Therapeutics has received a consensus analysts rating of 4.80. Therefore, it is recommended to buy RAPP.
- StrongBuy: 4
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 56.6 | 42.6% |
P/S = 93.1908
P/B = 3.9934
Revenue TTM = 20.0m USD
EBIT TTM = -119.1m USD
EBITDA TTM = -118.1m USD
Long Term Debt = 8.19m USD (estimated: total debt 10.8m - short term 2.62m)
Short Term Debt = 2.62m USD (from shortTermDebt, last quarter)
Debt = 10.8m USD (from shortLongTermDebtTotal, last quarter) (leases 10.8m already included)
Net Debt = -466.0m USD (calculated: Debt 10.8m - CCE 476.8m)
Enterprise Value = 1.40b USD (1.86b + Debt 10.8m - CCE 476.8m)
Interest Coverage Ratio = unknown (Ebit TTM -119.1m / Interest Expense TTM 0.0)
EV/FCF = -17.32x (Enterprise Value 1.40b / FCF TTM -80.7m)
FCF Yield = -5.77% (FCF TTM -80.7m / Enterprise Value 1.40b)
FCF Margin = -403.5% (FCF TTM -80.7m / Revenue TTM 20.0m)
Net Margin = -536.4% (Net Income TTM -107.3m / Revenue TTM 20.0m)
Gross Margin = 95.0% ((Revenue TTM 20.0m - Cost of Revenue TTM 1.00m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 2.81 (Enterprise Value 1.40b / Total Assets 497.6m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 10.8m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -94.1m (EBIT -119.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 27.08 (Total Current Assets 484.7m / Total Current Liabilities 17.9m)
Debt / Equity = 0.02 (Debt 10.8m / totalStockholderEquity, last quarter 471.5m)
Debt / EBITDA = 3.94 (negative EBITDA) (Net Debt -466.0m / EBITDA -118.1m)
Debt / FCF = 5.77 (negative FCF - burning cash) (Net Debt -466.0m / FCF TTM -80.7m)
Total Stockholder Equity = 432.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -26.83% (Net Income -107.3m / Total Assets 497.6m)
RoE = -24.79% (Net Income TTM -107.3m / Total Stockholder Equity 432.8m)
RoCE = -27.02% (EBIT -119.1m / Capital Employed (Equity 432.8m + L.T.Debt 8.19m))
RoIC = -19.56% (negative operating profit) (NOPAT -94.1m / Invested Capital 481.3m)
WACC = 12.53% (E(1.86b)/V(1.87b) * Re(12.60%) + D(10.8m)/V(1.87b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 12.60% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 71.91 | Cagr: 53.24%
[DCF] Fair Price = unknown (Cash Flow -80.7m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.55 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 4.0 | # QB: 1
EPS current Quarter (2026-06-30): EPS=-0.99 | Chg30d=+0.81% | Revisions=-38% | Analysts=7
EPS next Quarter (2026-09-30): EPS=-1.01 | Chg30d=-0.57% | Revisions=-12% | Analysts=7
EPS current Year (2026-12-31): EPS=-3.46 | Chg30d=+0.21% | Revisions=+38% | GrowthEPS=-21.1% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-4.40 | Chg30d=+1.59% | Revisions=-38% | GrowthEPS=-26.9% | GrowthRev=-100.0%
[Analyst] Revisions Ratio: -17% (up=8, down=12)